MC

467.75

+1.07%↑

SANES

9.917

+3.5%↑

SAF

287.5

+2.83%↑

BBVA

18.815

+3.49%↑

BNP

84.36

+3.15%↑

MC

467.75

+1.07%↑

SANES

9.917

+3.5%↑

SAF

287.5

+2.83%↑

BBVA

18.815

+3.49%↑

BNP

84.36

+3.15%↑

MC

467.75

+1.07%↑

SANES

9.917

+3.5%↑

SAF

287.5

+2.83%↑

BBVA

18.815

+3.49%↑

BNP

84.36

+3.15%↑

MC

467.75

+1.07%↑

SANES

9.917

+3.5%↑

SAF

287.5

+2.83%↑

BBVA

18.815

+3.49%↑

BNP

84.36

+3.15%↑

MC

467.75

+1.07%↑

SANES

9.917

+3.5%↑

SAF

287.5

+2.83%↑

BBVA

18.815

+3.49%↑

BNP

84.36

+3.15%↑

Search

Eurazeo SE

Avatud

SektorRahandus

40.74 2.11

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

39.74

Max

41.58

Põhinäitajad

By Trading Economics

Sissetulek

-309M

Müük

372M

283M

Kasumimarginaal

347.853

Töötajad

438

EBITDA

-256M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+87.15% upside

Turustatistika

By TradingEconomics

Turukapital

-353M

2.6B

Eelmine avamishind

38.63

Eelmine sulgemishind

40.74

Uudiste sentiment

By Acuity

50%

50%

171 / 441 Pingereas Finance

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Eurazeo SE Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. märts 2026, 23:31 UTC

Kuumad aktsiad

Stocks to Watch: Nike, RH, NCino

31. märts 2026, 22:35 UTC

Tulu

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1. apr 2026, 00:00 UTC

Omandamised, ülevõtmised, äriostud

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31. märts 2026, 23:50 UTC

Omandamised, ülevõtmised, äriostud

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31. märts 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31. märts 2026, 23:33 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31. märts 2026, 23:21 UTC

Tulu

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31. märts 2026, 23:14 UTC

Market Talk
Tulu

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31. märts 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Loss Widens >000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31. märts 2026, 22:36 UTC

Tulu

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31. märts 2026, 21:46 UTC

Omandamised, ülevõtmised, äriostud

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31. märts 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31. märts 2026, 21:35 UTC

Tulu

Nike Expects China Sales Down 20% in 4Q, CFO Says

31. märts 2026, 21:35 UTC

Tulu

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31. märts 2026, 21:35 UTC

Tulu

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31. märts 2026, 21:33 UTC

Omandamised, ülevõtmised, äriostud

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31. märts 2026, 21:33 UTC

Tulu

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31. märts 2026, 21:32 UTC

Tulu

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31. märts 2026, 21:28 UTC

Tulu

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31. märts 2026, 21:26 UTC

Tulu

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31. märts 2026, 21:25 UTC

Tulu

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31. märts 2026, 21:24 UTC

Market Talk
Tulu

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31. märts 2026, 21:22 UTC

Tulu

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31. märts 2026, 21:22 UTC

Tulu

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31. märts 2026, 21:21 UTC

Tulu

Nike's Digital Channel Still Too Promotional, CFO Says

31. märts 2026, 21:20 UTC

Tulu

Nike CEO: Converse Remains Important to Portfolio

Võrdlus sarnastega

Hinnamuutus

Eurazeo SE Prognoos

Hinnasiht

By TipRanks

87.15% tõus

12 kuu keskmine prognoos

Keskmine 72.5 EUR  87.15%

Kõrge 85 EUR

Madal 60 EUR

Põhineb 2 Wall Streeti analüütiku instrumendi Eurazeo SE 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

1

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

62.3 / N/AToetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

171 / 441 Pingereas Rahandus

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Eurazeo SE

Eurazeo SE is a private equity and venture capital firm specializing in growth capital, acquisitions, leveraged buyouts, and buy-ins of a private company, and investments in mid-market and listed public companies. The company invest in equity in the small-mid and Mid-large buyout segments. The firm seeks to invest in medium-sized or large companies, SMEs, high growth companies, and real estate management and investment activities. It does not have any restrictions regarding the sectors in which it invests but prefers to invest in smart cities, services, leisure and mobility, real estate, fintech, investment activities, distribution, industry, luxury, consumer goods, business services, consumer and retail brands, and health sectors. The firm seeks to invest in consumer brands with a focus on beauty, personal care, household care, juvenile products, apparel, wellness, accessories, home, jewellery, leisure, health, fitness, beverage, and food companies based in United States and Europe. It typically invests in companies with a differentiated concept and global growth potential. The firm identifies companies upstream, carefully selecting them primarily from sectors driven by digital transformation and focusing on changes in lifestyle and consumption (mobility, online buying, collaboration models, etc. The firm invests in large properties in need of restructuring; residential, commercial, and office development projects; and companies with real estate assets in Western Europe. It primarily invests in United States, France, Italy, North America and other European countries. It seeks to invest between "50 million ($54.35 million) to "250 million ($271.77 million) in small mid buyout business. It seeks to invest between "25 million ($27.18 million) to "100 million ($108.71 million) in growth business. It seeks to invest between "10 million ($10.82 million) and "40 million ($43.82 million) in the fields of healthcare research. It seeks to invests between equity investment between "1 million ($1.17 million) and "559.01 mil
help-icon Live chat